Syndetics omslagsbild
Bild från Syndetics

Schering-Plough and concerns about Vytorin / Dhanishtha Kika Bhagwangar, Matthew R. Smith, James S. O'Rourke.

Av: Medverkande: Materialtyp: TextSerie: Utgivningsuppgift: London : SAGE Publications Ltd, 2017Beskrivning: 1 online resource : illustrationsInnehållstyp:
  • text
Medietyp:
  • computer
Bärartyp:
  • online resource
ISBN:
  • 9781526404909 (ebook) :
Ämnen: DDK-klassifikation:
  • 338.4761699406
Onlineresurser: Clinical tests showed cholesterol drug Vytorin was not living up to the claims of the producers, Schering-Plough and Merck. Consumers could receive a virtually equivalent drug for one-third of the cost. The problem facing Schering-Plough was to find the best methods to reach its stakeholders and ensure them that their concerns will be addressed in a timely and effective manner. This case has health, financial, and legal ramifications for stakeholders.
Inga fysiska exemplar för denna post

Originally published: Bhagwangar, D.K., Smith, M.R., & ORourke, J. S. (2008). Schering-Plough and concerns about Vytorin. 08-11. Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame.

Clinical tests showed cholesterol drug Vytorin was not living up to the claims of the producers, Schering-Plough and Merck. Consumers could receive a virtually equivalent drug for one-third of the cost. The problem facing Schering-Plough was to find the best methods to reach its stakeholders and ensure them that their concerns will be addressed in a timely and effective manner. This case has health, financial, and legal ramifications for stakeholders.

Description based on XML content.

Licensed e-book